insights_auto
Nega DMYD-B oshdi 3,35%?
Batafsil oʻrganishchevron_right
DMYD-B:STO
Diamyd Medical AB
1,05Â SEK
arrow_upward
+3,35%(+0,034) 1K
13-okt, 16:07:25 (GMT+2) · SEK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoDMYD-B tikeri uchun statistika yaratilmoqda...
Ochish
1,03Â SEK
Yuqori
1,08Â SEK
Past
1,01Â SEK
Bozor kapitali
158,75Â mln
Oʻrtacha hajm
796,34Â ming
Hajmi
691,40Â ming
52 haftalik eng yuqori
17,88Â SEK
52 haftalik eng past
0,90Â SEK
Aksiya boʻyicha daromad
-1,76Â SEK
Muomaladagi aksiyalar
134,00Â mln
Xodimlar soni
42
Ochish
1,03Â SEK
Yuqori
1,08Â SEK
Past
1,01Â SEK
Bozor kapitali
158,75Â mln
Oʻrtacha hajm
796,34Â ming
Hajmi
691,40Â ming
52 haftalik eng yuqori
17,88Â SEK
52 haftalik eng past
0,90Â SEK
Aksiya boʻyicha daromad
-1,76Â SEK
Muomaladagi aksiyalar
134,00Â mln
Xodimlar soni
42
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
GlobeNewswire
·
1 soat oldin
Primech Holdings (Nasdaq: PMEC) to Present at LD Micro Main
Stock Titan
·
1 soat oldin
$1 bid-price compliance regained, but NeuroSense (Nasdaq: NRSN) still faces a listing deficiency.
CNBC
·
27 daqiqa oldin
Opening Bell: October 13 2026
Profil
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Diamyd Medical AB haqida